Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/38993
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Data de embargo
2021-01-06
Coleções
- INI - Artigos de Periódicos [3398]
Metadata
Mostrar registro completo
EXPRESSION ANALYSIS OF DOPAMINE RECEPTOR SUBTYPES IN NORMAL HUMAN PITUITARIES, NONFUNCTIONING PITUITARY ADENOMAS AND SOMATOTROPINOMAS, AND THE ASSOCIATION BETWEEN DOPAMINE AND SOMATOSTATIN RECEPTORS WITH CLINICAL RESPONSE TO OCTREOTIDE-LAR IN ACROMEGALY
Autor(es)
Afiliação
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
University of Illinois. Department of Medicine. Section of Endocrinology, Diabetes and Metabolism. Chicago, Il, USA / Jesse Brown Veterans Affairs Medical Center. Chicago, Il, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Serviço de Neurocirurgia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Serviço de Patologia Clínica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Setor de patologia. Rio de Janeiro, RJ, Brasil.
Hospital Santa Casa de Misericórdia do Rio de Janeiro. Neurosurgery Section. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Instituto de Biofísica Carlos Chagas Filho. Rio de Janeiro, RJ, Brasil.
University of Illinois. Department of Medicine. Section of Endocrinology, Diabetes and Metabolism. Chicago, Il, USA / Jesse Brown Veterans Affairs Medical Center. Chicago, Il, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
University of Illinois. Department of Medicine. Section of Endocrinology, Diabetes and Metabolism. Chicago, Il, USA / Jesse Brown Veterans Affairs Medical Center. Chicago, Il, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Serviço de Neurocirurgia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Serviço de Patologia Clínica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Setor de patologia. Rio de Janeiro, RJ, Brasil.
Hospital Santa Casa de Misericórdia do Rio de Janeiro. Neurosurgery Section. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Instituto de Biofísica Carlos Chagas Filho. Rio de Janeiro, RJ, Brasil.
University of Illinois. Department of Medicine. Section of Endocrinology, Diabetes and Metabolism. Chicago, Il, USA / Jesse Brown Veterans Affairs Medical Center. Chicago, Il, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Endocrinologia. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Context: Dopamine receptor (DR) and somatostatin receptor subtype expression in pituitary adenomas may predict the response to postsurgical therapies. Objectives: Our objectives were to assess and compare the mRNA levels of DR1-5 and somatostatin receptors 1–5 in normal pituitaries (NPs), nonfunctioning pituitary adenomas (NFPAs), and somatotropinomas. In addition, we determined whether the level of DR expression correlates with the in vivo response to octreotide-LAR in acromegalic patients. Design and Patients: Eight NPs, 30 NFPAs, and 39 somatotropinomas were analyzed for receptor mRNA levels by real-time RT-PCR. The DR2 short variant was estimated as the DR2 long/DR2 total (DR2T). The relationship between DR expression and the postsurgical response to octreotide-LAR was assessed in 19 of the acromegalic patients. Results: DR3 was not detected. The relationship between expression levels of DR subtypes in NPs and somatotropinomas was DR2T ≫≫DR4≫DR5>DR1, whereas in NFPAs, DR2T ≫≫ DR4≫DR1>DR5. The DR2 short variant was the predominant DR2 variant in the majority of samples. In acromegalics treated with octreotide-LAR, DR1 was negatively correlated with percent GH reduction (3 months: r = - 0.67, P = 0.002; and 6 months: r = - 0.58, P = 0.009), and DR5 was positively correlated with percent IGF-I reduction (3 months: r = 0.55, P = 0.01; and 6 months: r = 0.47, P = 0.04). Conclusions: DR2 is the predominant DR subtype in NPs, NFPAs, and somatotropinomas. The fact that DR1, DR4, and DR5 are also expressed in many adenomas tested suggests that these receptors might also play a role in the therapeutic impact of postsurgical medical therapies in patients with NFPA and acromegaly. This was supported by the finding that the in vivoresponse to octreotide-LAR was negatively associated with DR1 and positively associated with DR5.
Compartilhar